INVACARE CORPORATION (NYSE:IVC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Corporation (the Company) elected Susan H. Alexander as a member
of the Companys Board of Directors, effective December 1, 2016,
on the unanimous recommendation of the Nominating and Governance
Committee of the Board of Directors. Ms. Alexander has been
elected to serve a term expiring at the Companys 2017 Annual
Meeting of Shareholders. Ms. Alexander has been appointed to the
Companys Regulatory and Compliance Committee.
President, Chief Legal Officer and Corporate Secretary of Biogen
Inc., a biopharmaceutical company, since December 2011. Prior to
that, from 2006 to December 2011, Ms. Alexander served as
Executive Vice President, General Counsel and Corporate Secretary
of Biogen Inc. From 2003 to January 2006, Ms. Alexander served as
the Senior Vice President, General Counsel and Corporate
Secretary of PAREXEL International Corporation, a
biopharmaceutical services company. From 2001 to 2003, Ms.
Alexander served as General Counsel of IONA Technologies, a
software company. From 1995 to 2001, Ms. Alexander served as
Counsel at Cabot Corporation, a specialty chemicals and
performance materials company. Prior to that, Ms. Alexander was a
partner at the law firms of Hinckley, Allen Snyder and Fine
Ambrogne. Ms. Alexander is a graduate of Wellesley College and
Boston University School of Law.
and any other person to which Ms. Alexander was elected as a
director of the Company. Ms. Alexander has not entered into any
related party transactions with the Company that are required to
be disclosed to Item 404(a) of Regulation S-K.
current program for the compensation of non-employee directors,
which is described under the caption Compensation of Directors in
the Companys Definitive Proxy Statement on Schedule 14A filed
with Securities and Exchange Commission on April 8, 2016. In
accordance with the director compensation program, on December 1,
2016, Ms. Alexander will receive a grant of 2,839 restricted
stock units under the Companys 2013 Equity Compensation Plan.
announcing the election of Ms. Alexander to the Board of
Directors, which is attached as Exhibit 99.1 to this Current
Report on Form 8-K.
|
(d) Exhibits.
|
|
|
Exhibit Number
|
Description of Exhibit
|
|
99.1
|
Press Release, dated November 28, 2016.
|
About INVACARE CORPORATION (NYSE:IVC)
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific. The Company manufactures and distributes three product categories: mobility and seating, lifestyle and respiratory therapy. It provides medical device solutions for congenital (cerebral palsy, muscular dystrophy and spina bifida), acquired (stroke, spinal cord injury, traumatic brain injury, post-acute recovery and pressure ulcers) and degenerative (amyotrophic lateral sclerosis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly and bariatric) ailments. The Company sells its products to home medical equipment providers with retail and e-commerce channels, residential living operators, distributors and government health services. INVACARE CORPORATION (NYSE:IVC) Recent Trading Information
INVACARE CORPORATION (NYSE:IVC) closed its last trading session 00.00 at 11.75 with 168,058 shares trading hands.
